Library

By pinki shah / May 14, 2022

Displaying 1,676 - 1,700 of 2,995

Targeted Therapy in Lung Cancer

Targeted Therapy in Lung Cancer

By: Edgardo S. Santos, MD, FACP

Advances in Targeted Therapy in Lung Cancer

Advances in Targeted Therapy in Lung Cancer

By: Edgardo S. Santos, MD, FACP

Advances in Targeted Therapy in Lung Cancer

Advances in Targeted Therapy in Lung Cancer

By: Edgardo S. Santos, MD, FACP

EGFR PKI Resistance and K-RAS Mutations

EGFR PKI Resistance and K-RAS Mutations

By: Edgardo S. Santos, MD, FACP

Metastatic Targeted Therapy Updates

Metastatic Targeted Therapy Updates

By: Edgardo S. Santos, MD, FACP

New Developments in EGFR and K-RAS Therapies in NSCLC

New Developments in EGFR and K-RAS Therapies in NSCLC

By: Edgardo S. Santos, MD, FACP

Front Line Targeted Therapy in NSCLC: Tyrosine Kinase Inhibitors

Front Line Targeted Therapy in NSCLC: Tyrosine Kinase Inhibitors

By: Edgardo S. Santos, MD, FACP

New Developments in EGFR and K-RAS Therapies in NSCLC

New Developments in EGFR and K-RAS Therapies in NSCLC

By: Edgardo S. Santos, MD, FACP

Front Line Targeted Therapy in NSCLC: Tyrosine Kinase Inhibitors

Front Line Targeted Therapy in NSCLC: Tyrosine Kinase Inhibitors

By: Edgardo S. Santos, MD, FACP

EGFR and Resistant Mechanisms

EGFR and Resistant Mechanisms

By: Edgardo S. Santos, MD, FACP, FASCO

Master Lecture on Targeting NSCLCDriver Pathways

Master Lecture on Targeting NSCLCDriver Pathways

By: Edgardo S. Santos, MD, FACP, FASCO

Updated Management on Advanced NSCLC Driver Mutant Tumors

Updated Management on Advanced NSCLC Driver Mutant Tumors

By: Edgardo S. Santos, MD, FACP, FASCO

Lung Cancer Session

Lung Cancer Session

By: Edgardo S. Santos, MD, FACP, Janakiraman Subramanian, MD, MPH,Luis E Raez, MD, FACP, FCCP, Mark A. Socinski, MD,

Dealing with EGFRex19del & L858R, ALK, and K-RasG12C Genetic Aberrations

Dealing with EGFRex19del & L858R, ALK, and K-RasG12C Genetic Aberrations

By: Edgardo Santos, MD

Non-Small Cell Lung Cancer: EGFR, ALK, & K-Ras Pathways

Non-Small Cell Lung Cancer: EGFR, ALK, & K-Ras Pathways

By: Edgardo Santos, MD, FACP

Targeted Therapy in Non-Squamous NSCLC: Where Are We and What is Coming Up

Targeted Therapy in Non-Squamous NSCLC: Where Are We and What is Coming Up

By: Edgardo Santos, MD, FACP

EGFR and Resistant Mechanisms

EGFR and Resistant Mechanisms

By: Edgardo Santos, MD, FACP

EGFR and Resistant Mechanisms

EGFR and Resistant Mechanisms

By: Edgardo Santos, MD, FACP

Small Cell Lung Cancer

Small Cell Lung Cancer

By: Erin Schenk, MD, PhD

Small Cell Lung Cancer

Small Cell Lung Cancer

By: Erin Schenk, MD, PhD

Immunotherapy Toxicities and Lung Biomarkers

Immunotherapy Toxicities and Lung Biomarkers

By: Erin Schenk, MD, PhD

Immunotherapy Toxicities and Lung Biomarkers

Immunotherapy Toxicities and Lung Biomarkers

By: Erin Schenk, MD, PhD

Updates in Treatment of Early Stage and Locally Advanced NSCLC

Updates in Treatment of Early Stage and Locally Advanced NSCLC

By: Erminia Massarelli, MD, PhD, MS

Updates in Treatment of Early Stage and Locally Advanced NSCLC

Updates in Treatment of Early Stage and Locally Advanced NSCLC

By: Erminia Massarelli, MD, PhD, MS

Updates in Treatment of Early Stage and Locally Advanced NSCLC

Updates in Treatment of Early Stage and Locally Advanced NSCLC

By: Erminia Massarelli, MD, PhD, MS